Based on these data, we speculated that the wt-EGFR inhibitor BA might be a potential sensitizer mediating resistance to EGFR-TKIs in lung cancer cells expressing wt-EGFR and that treatment with BA plus EGFR-TKI is a promising combination therapy for intractable NSCLC harboring wt-EGFR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.